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Chronic pain affects 20-30% of the adult population in western countries, with musculoskeletal 52 disorders being the most common cause. 1,2 Opioids have been reported to be increasingly used to 53 treat chronic pain conditions, including pain caused by musculoskeletal disorders, 3,4 and sales of 54 opioids in the US have been reported to have quadrupled from 1999 to 2010. 5 Further, it has been 55 estimated that patients with non-cancer chronic pain conditions account for more than 2/3 of the 56 total opioid consumption. 6 Opioids are potent analgesic pharmaceuticals but often have side effects 57 such as nausea, constipation, and somnolence, and usage is associated with a high risk of 58 addiction .7-9 For older people using opioids to treat chronic pain conditions the risk of side effects is 59 further amplified by coexisting co-morbidities and risk of drug-drug interactions. 10 Similarly, the 60 risk of falls is also increased when using medications acting on the central nervous system such as 61 opioids in older people 11, 12 including for patients with osteoarthritis (OA). 13 
62
OA is one of the major and steadily growing chronic musculoskeletal pain conditions in the middle-63 aged and elderly population, 2 with more than 250 million people world-wide suffering from knee 64 OA alone according to the Global Burden of Disease Study. 14 International clinical guidelines are 65 reluctant with recommending opioids for patients with knee and hip OA as the risk-benefit of opioid 66 use is uncertain. 15, 16 End-stage treatment for patients with knee or hip OA is total joint replacement. 67
Similar to other major surgical procedures about 7% of patients undergoing total knee or hip joint 68 replacement show persistent use of opioids in the year following their surgery, potentially 69 amplifying the risk of addiction. 17, 18 Both long-term preoperative and postoperative opioid use after 70 knee and hip replacement surgery, respectively, has been reported to be associated with increased 71 risk of revision surgery. 19,20 72 Even though several warning flags have been raised in the literature concerning opioid use by OA 73 patients, 21-23 much uncertainty remains. For instance, there is great paucity of data describing opioid 74 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 use in OA patients, especially in the context of overall opioid use in comparison to the general 75 population, and the proportion of total opioid prescriptions that are attributable to OA is largely 76 unknown. Such information is important for understanding the utilization of opioids in a large 77 group of chronic pain patients. 78
Thus, the aims of our study were: i) to estimate the point prevalence and annual period prevalence 79 as well as the incidence rate of dispensed weak and strong opioid in patients with and without knee 80 and hip OA, using data from an entire geographically well-defined population in southern Sweden; 81 ii) to estimate the proportion of dispensed weak and strong opioids in the general population ≥35 82 years attributable to knee and/or hip OA (or its related comorbidities). 83
84

METHODS 85
Data sources 86
In Sweden, healthcare is provided from both public and private healthcare providers through the 87 same tax-based financing system. All Swedish residents have a personal identification number, 88 which includes information on age and sex. Swedish law requires all healthcare providers to submit 89 information about healthcare contacts for reimbursement purposes. In the southernmost region of 90
Sweden, covering about one-eighth of the Swedish population, all healthcare visits (both public and 91 private) are registered within the Skåne Healthcare Register (SHR). 24 The data is stored using each 92 individual's unique personal identification number and contact date. Furthermore, the register 93 contains the publicly practicing physicians' diagnostic codes according to the International 94 Classification of Diseases (ICD) 10 system. The physicians themselves assign these codes, which 95 are retrieved from the electronic medical records into the SHR. We defined persons with at least one diagnostic code for knee OA (ICD-10 code: M17) or hip OA 106 (M16) in the period between Jan 1 s 1998 and Oct 31 st 2015 as having prevalent knee or hip OA. 107
Participants with no record/s of either knee or hip OA diagnosis in the same period were defined as 108 not exposed to knee or hip OA. Persons with both diagnoses were classified as having both knee 109 and hip OA. 110 111
Prevalent and incident opioid use 112
We identified all dispensed opioid prescriptions through SPDR between Nov 1 st 2013 and Oct 31 st 113 2015 using Anatomical Therapeutic Chemical (ATC) codes from group N02A. We classified 114 opioids as either 'weak' (i.e. Codeine and Tramadol) or 'strong' (i.e. Morphine, Oxycodone (incl. 115 combinations), Fentanyl, Buprenorphine, Ketobemidone, Tapentadol, Hydromorphone, Pentazocine 116 and Pethidine) as described in the 'Recommendations for the appropriate use of opioids for 117 persistent non-cancer pain'. 25 If a person had an active prescription of both weak and strong opioids 118 prescribed at the same time, we included this person in calculations related to both types of opioids. 119
However, in calculations of any dispensed opioid, this person was included only once. 120 Dispensed opioid incidence rates are presented per 1000 person-years with 95% CI, crude and age-137 and sex-standardized to the Skåne population at risk for opioid use. The 95% CIs for the crude 138 proportions were calculated using the Agresti-Coull method and for crude incidence rates as mean 139 of Poisson distribution, taking the time at risk into account. The 95% CIs for standardized 140 proportions and rates were calculated using the function dstdize in Stata. 26 As recent surgery is 141 associated with opioid use for postoperative pain, we also report incidence rates excluding any 142 dispensed opioids 0-30 days after a surgical procedure, calculated from the discharge date and 143 performed a sensitivity analysis to assess the impact of OA on opioid use that is not directly related 144 to surgical treatment. Dispensed opioid prevalence ratios and incidence rate ratios were estimated 145 using Poisson regression models with robust standard errors. Models were adjusted for age, sex,
income category, highest education level reached, residential area, civil status and country of birth 147 (Sweden vs others). Finally, we calculated the population attributable fractions (PAF) of dispensed 148 opioid incidence rates derived from the Poisson models, by calculating ratio of conditional 149 predicted incidence rates with 95%CI in a true observed scenario as in our data compared to a 150 hypothetical scenario where no one would have OA. 27 prevalent hip OA only, and 9265 (1%) had both prevalent knee and hip OA. In general, more 157 women than men had prevalent knee or hip OA, and individuals with OA were older than those 158 without OA (Table 1) . 159
The 12-month period prevalence of any dispensed opioid among individuals with knee and/or hip 160 OA was 23.6% (95% CI 23.3, 24.2) compared with 9.6% (95% CI 9.6, 9,7) among those without 161 knee or hip OA, corresponding to a 12-month prevalence ratio of 2.1 (95% CI 2.1, 2.1) ( Table 2) . 162
Point prevalence estimates showed that 4.6% (95% CI 4.4, 4.9) of patients with knee and/or hip OA 163 had an active dispensed prescription of an opioid on Oct 4 th 2015. Similarly, dispensing incidence 164 rates (i.e. new opioid use) of any opioid among those without dispensed opioids in the preceding 165
year were 2.3-fold higher (95% CI 2.3, 2.4) among those with knee and/or hip OA compared to 166 those without (Table 3 ). Our data showed that 11.8% (95% CI 11.3, 12.3) of any new (i.e. incident) 167 opioid prescription dispensed were to a patient with knee and/or hip OA (i.e. PAF). 168
In general, 12-month period prevalence ratios and incidence rate ratios for dispensing of weak 169 opioids were similar between patients with either knee or hip OA, but somewhat higher among 170
those with combined knee and hip OA ( Table 2 and 3) . However, prevalence ratios and incidence 171 rate ratios for dispensing of strong opioids were higher among patients with hip OA and patients 172 with combined knee and hip OA than patients with knee OA alone ( Table 2 and 3). The PAF of 173 knee and/or hip OA for incident strong and weak opioids dispensed were 16.7% (95% CI 15.7, 174 17.6) and 9% (95% CI 8.4, 9.5), respectively. Age-stratified incidence rates showed that dispensing 175 of weak opioids among patients with knee and/or hip OA decreased with increasing age, whereas 176 the opposite pattern was observed for strong opioids (Figure 1 and 2) . Excluding opioid use within 177 the 30 days following discharge after a surgical treatment attenuated the estimates of incidence rates 178 for dispensed strong opioids markedly (Table 3) , although the incidence rate ratios remained 179 essentially the same (Supplementary table 1) . 180
The most common dispensed opioid among those with an incident opioid prescription was Codeine, 181 which accounted for 43% of all incident dispensations, followed by Oxycodone (incl. 182 combinations) (28%), Tramadol (16%) and Morphine (11%). However, the proportion of incident 183 dispensations of weak versus strong opioids differed between individuals with knee and/or hip OA 184 and those without. Among patients with knee and/or hip OA, strong opioids accounted for a higher 185 proportion of total incident dispensations, particularly Oxycodone (38% vs. 26%) and Morphine 186 (14% vs. 10%). Conversely, in individuals without OA, weak opioids accounted for a higher 187 proportion of incident dispensations, such as Codeine (46% vs. 33%) and Tramadol (17% vs. 12%) 188
( Supplementary table 2 ). This picture remained the same when excluding opioid use within 30 days 189 after discharge from a surgical procedure ( Supplementary table 3) . the same period. Our results suggest that patients with knee and/or hip OA are therefore over 2 196 times more likely to have an opioid dispensed. Furthermore, patients with knee and/or hip OA were 197 also twice as likely to start a new opioid prescription compared to individuals without OA. Finally, 198 we report that 12% of new opioid use is attributable to knee and/or hip OA and/or their related 199
comorbidities. 200 201
Use of opioids for chronic pain conditions has been reported to be increasing within recent years. 4 202
Some studies have reported on opioid use in patients with knee and hip OA, 21-23,29 but in general, 203 population-based estimates on current and new prescriptions for opioid use in individuals with knee 204 and hip OA are still sparse. Our data suggest that 4-5% of individuals with doctor-diagnosed knee 205 and/or hip OA have an active opioid prescription at any given time. Estimates were highest for the 206 1% of individuals having combined knee and hip OA. The likelihood of having a new opioid 207 dispensed was also higher among individuals with knee and/or hip OA, compared to the population 208 without knee or hip OA. This likelihood was higher for strong opioids, yielding an incidence rate 209 ratio of 2.6 compared to 2.1 for weak opioids. Particularly, a much higher proportion of individuals 210 with knee and/or hip OA had a new prescription for Oxycodone, compared to those without OA. 211
To the best of our knowledge, we are the first to report prevalence and incidence estimates of 212 dispensed opioids among patients with prevalent knee and/or hip OA based on data from an entire 213 population, and thus we have identified no data for direct comparison. It has previously been 214 reported that the proportion of people with an opioid prescription has been stable in Sweden in the 215 period from 2006-2015. 30 Nevertheless, our data still suggest that patients with knee and hip OA 216 constitute a group of chronic pain patients with alarmingly high rates of opioid use, particularly M A N U S C R I P T
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since 9% and 17% of newly dispensed weak and strong opioids, respectively, can be attributed to 218 knee and/or hip OA and their related comorbidities. 219
The high rates of opioid dispensing for patients with knee and/or hip OA is controversial given the 220 reluctance of clinical guidelines for recommending opioids for OA patients due to risk of adverse 221 events and additction. 15, 16 Paradoxically, first-line guideline recommended treatment such as 222 exercise therapy, 31,32 which is safe, 33 shows similar or greater effect sizes than pharmacological 223 treatments such as paracetamol, NSAIDs 34 and opioids 35, 36 in comparison with control interventions 224 or placebo for reducing knee and hip OA pain. However, quality of care studies report that exercise 225 therapy is heavily underutilized, 37,38 and it may be speculated that the perception of strong pain 226 medication as an 'easy and quick fix' solution may present a barrier for utilization of more safe and 227 effective treatments. Adding to this, opioid use has been associated with increased healthcare 228 utilization and cost, especially among individuals with long-term use. 39 229
Surgeries such as knee arthroscopy and joint replacements are common among patients with knee 230 or hip OA, and time-limited postoperative use of opioids is often standard. However, more than 7% 231 of patients undergoing total hip or knee joint replacement show persistent use of opioids, in the year 232 following joint replacement, which can lead to addiction. 17 In sensitivity analyses we sought to take 233 recent surgery into account by excluding opioid use within the first 30 days from discharge after a 234 surgical procedure. As expected, incidence rates of dispensed strong opioids were substantially 235 lowered. However, incidence rate ratios between individuals with knee and/or hip OA and the 236 population without OA were only marginally attenuated, suggesting that opioid use is elevated in 237 persons with OA not undergoing surgery or can persist long after surgical intervention. 238
Certain important considerations should be made in interpreting this study. One limitation is that we 239 as being OA-related when assessing the 12-month prevalence (in the period Nov 1 st to Oct 31 st 242 2015). However, OA is a slowly developing disease, often taking years to develop. Therefore, we 243 assume that opioid use close to OA diagnosis is still likely to be disease-related. Misclassification 244 of disease is also always a source of concern in such register-based studies. However, the validity of 245 the doctors' diagnostic coding in the SHR has been reported to be high. 40 Further, in Sweden only 2 246 of 3 persons with symptomatic knee OA consult healthcare, 41 and we were not able to assess opioid 247 use in those who did not consult a physician. However, opioids can only legally be prescribed by 248
physicians. 249
Based on the current data, it was not possible to determine what condition the prescribed opioids 250
were prescribed for as no diagnosis was available as part of the dispensing data. We chose not to 251 adjust our analysis for the presence of other diagnosis, which may be related to opioid use because 252 it is not known if these co-morbidities precede or follow as a consequence of knee and/or hip OA. 253
As with all studies using data on dispensed drugs, we do not know what percentage of all prescribed 254 opioids were dispensed, and the patient compliance in relation to dispensed drugs. 255
Finally, we performed sensitivity analyses assessing point prevalence of opioid use on the 4 th of 256 January, April and July (data not shown), which provided similar estimates to those for Oct 4 th , 257
presented in this study. This suggests negligible effects of the choice of day on the point prevalence 258
assessment. 259
In conclusion, we found that approximately one in every four individuals with knee and/or hip OA 260 had opioids dispensed within a 12-month period, which was more than twice as many as among the 261 population without knee or hip OA. Similarly, individuals with knee and/or hip OA were more than 262 twice as likely to have a new (incident) dispensation of an opioid compared to those without OA. 263
Recent surgery accounted for a considerable proportion of strong opioid use, however incidence 264 rate ratios between individuals with and without knee and/or hip OA was only marginally affected older, 9% of weak and 17% of strong opioids, respectively, could be attributed to knee and/or hip 267
OA and/or their related comorbidities. These results highlight that patients with knee and hip OA 268 are an important group of patients having an alarmingly high use of prescription opioids. Findings 269 call for increased awareness and better utilization of other core OA treatments, as well as point to a 270 general need for better management of OA as a growing public health concern. 271 272
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We would like to acknowledge Velocity Hughes, PhD, for her contribution to the manuscript with 274 language editing. with prevalent knee and/or hip osteoarthritis compared with individuals without knee or hip osteoarthritis. The y-axis is broken to accommodate the high value of the upper confidence limit for the youngest age group. 
